Migard (Frovatriptan)

• Frovatriptan belongs to the triptan class and is used to treat migraine‑related conditions.
• Migraine attack (with or without aura): provides rapid relief of headache pain and associated symptoms.
• Menstrual migraine: alleviates attacks that occur in relation to the menstrual cycle.
• Adult migraine (age ≥ 18): suitable for patients needing an oral triptan for acute episodes.

• Frovatriptan acts as an agonist at 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of these receptors produces cranial vasoconstriction and inhibits the release of vasoactive neuropeptides, thereby reducing migraine pain and associated neurological symptoms.

Frovatriptan may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Dizziness: transient light‑headedness.
• Fatigue: feeling of tiredness.
• Dry mouth: reduced salivation.
• Chest discomfort: pressure or tightness in the chest.
• Tingling: paresthesia in extremities.

Serious or Rare Side Effects

• Coronary vasospasm: reduced blood flow to the heart.
• Severe hypertension: sudden high blood pressure.
• Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Myocardial infarction: rare heart attack occurrence.

• Before prescribing Frovatriptan, clinicians should evaluate patient history and potential risks.
• Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke.
• Avoid in uncontrolled hypertension: ensure blood pressure is well‑controlled.
• Screen for drug interactions: check concurrent serotonergic medications.
• Use caution in patients over 65: monitor for increased sensitivity.
• Pregnancy and lactation: evaluate benefit‑risk ratio as safety data are limited.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Frovatriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension and serotonin syndrome.
• Other triptans or ergot alkaloids: additive vasoconstrictive effects.
• SSRIs/SNRIs: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance blood pressure‑lowering effects.
• Oral contraceptives: possible alteration of efficacy.
• CYP1A2 inhibitors (e.g., fluvoxamine): may increase Frovatriptan plasma levels.